A Phase 2 interventional study of THC and CBD Mixture in Neoplasms Pancreatic, Cachexia; Cancer and Cannabis, sponsored by Jens Rikardt Andersen. Withdrawn at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-18.
Sponsored by Jens Rikardt Andersen · Phase 2, Interventional, and Treatment
Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test the appetite stimulating effects of CBD in patients with pancreatic cancer in palliative treatment.
Randomization of consecutive patients who wanted to participate to a daily dose of CBD or not as a supplement to the standard treatment.
3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,007 are open to participants now.
Browse Pancreatic Neoplasms studies →Jens Rikardt Andersen is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks
Drug: THC and CBD Mixture
32 patients with palliative pancreatic cancer, no experimental treatment,
Drug page: Nabiximols
Individually titrated doses on daily basis
Also known as: Medical cannabis oral drops
Energy and protein intake
Dietary history (% of estimated needs - NRS 2002)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Lean body mass
Bioimpedance (% of body weight, kg)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Appetite 1
VAS (cm on 10 cm scale)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Appetite 2
Dietary history (VAS (cm on 10 cm scale))
Time frame: The outcome measure will be assessed at day 0 and at week 4
Appetite 3
EORTC QLQ-C30 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Appetite 4
EORTC QLQ-PAN26 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Quality of life 1
EORTC QLQ-C30 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Quality of life 2
EORTC QLQ-PAN26 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Quality of life 3
VAS (VAS (cm on 10 cm scale))
Time frame: The outcome measure will be assessed at day 0 and at week 4
Pain 1
EORTC QLQ-C30 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Pain 2
EORTC QLQ-PAN26 (score, standard for the Quality of Life entity)
Time frame: The outcome measure will be assessed at day 0 and at week 4
Pain 3
VAS (VAS (cm on 10 cm scale))
Time frame: The outcome measure will be assessed at day 0 and at week 4
Mortality (8 weeks)
Patient records, national register
Time frame: 8 weeks
Plan to share: No
This study is withdrawn, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nabiximols
Jens Rikardt Andersen